Liver-directed gene therapy using adeno-associated viral vectors (AAV) has been demonstrated in preclinical models to correct several metabolic disorders stably and is currently being pursued in clinical trials for treatment of hemophilia A and B, ornithine transcarbamylase deficiency , and alpha1antitrypsin deficiency. [6] [7] [8] [9] Recently, we have demonstrated the
F amilial hypercholesterolemia (FH) is an autosomal codominant disorder characterized by the absence of the receptor for low-density lipoproteins (LDLR), a single chain glycoprotein containing 839 amino acids in its mature form. 1 Patients with 1 abnormal allele (heterozygous FH) have moderate elevations in plasma LDL and have premature coronary artery disease, whereas patients with homozygous FH (hoFH) have high serum LDL-C concentrations that cause early onset of life-threatening cardiovascular disease. 2 Current treatment options for hoFH include treatment with cholesterol-lowering drugs, 3 LDL apheresis, 4 and orthotopic liver transplantation, 5 all of which have substantial limitations. effectiveness of AAV-mediated gene therapy in correcting serum cholesterol levels in humanized mouse models of FH. 10 In these mice, systemic administration of AAV8 expressing human LDLR (AAV8.hLDLR) led to a lowering of cholesterol to normal levels by day 7, which was sustained for more than a year and led to the regression of preexisting atherosclerosis. However, AAV8.LDLR transduction was dose dependent, and statistically significant correction was only achieved at a vector dose of ≥1.5×10 11 GC/kg. For clinical gene therapy, minimizing the vector dose is critical for many reasons, including vector toxicity, immune response, and manufacturing constraints.
Hepatic LDLR expression is modulated by multiple pathways within the cell: LDLR transcription is regulated by the serum response element binding proteins, and HMG-CoA (3-hydroxy-3-methyl-glutaryl-CoA) reductase inhibitors (statins) activate serum response element binding proteins by inhibiting cholesterol synthesis within hepatocytes. 11 A second pathway of LDLR regulation, involving proprotein convertase subtilisin/kexin type 9 (PCSK9), was discovered based on human genetic gain-of-function mutations that caused high LDL-C levels 12 and loss-of-function mutations that caused low LDL-C levels. 13 Importantly, the loss of PCSK9 function was associated with a 88% reduction in cardiovascular disease and has led to the development of a new class of cholesterollowering drugs based on the inhibition of PCSK9. 14, 15 A third pathway of LDLR regulation was discovered by Zelcer et al, 16 who demonstrated the degradation of LDLR by inducible degrader of LDLR (IDOL). An E3 ubiquitin ligase, IDOL was induced after the activation of liver X receptors and subsequently interacted with the cytoplasmic tail of LDLR in mediating receptor ubiquitination and degradation. Furthermore, screening of subjects with low LDL-C identified loss-of-function mutations in IDOL that prevented degradation of LDLR. 17 It is likely that AAV8.LDLR expression is influenced by multiple regulatory pathways that control receptor expression. Importantly, patients with FH have significantly higher plasma levels of PCSK9. 18 The negative effect of post-transcriptional receptor regulation may be more pronounced when transduction efficiencies are suboptimal or when administering vector at lower doses, which is the expected results in humans with current AAV technology. In the present study, we evaluated the hypothesis that engineered variants of human LDLR with reduced affinity for PCSK9 or IDOL are more effective in lowering cholesterol in hoFH mice stably expressing human PCSK9 or human IDOL.
Methods
Animal studies were performed in accordance with the University of Pennsylvania, Institutional Review Board. LDLR −/− , APOBEC-1 −/− double knockout (DKO) and LDLR −/− , APOBEC-1 −/− , human ApoB100 transgenic mice were injected via tail vein for vector administration and serum collected by retro-orbital bleeds. At the end of study, animals were euthanized and livers were harvested for analysis. Vectors were obtained from the Vector Core at the University of Pennsylvania and expressed cDNAs for hLDLR, hPCSK9, or hIDOL driven from a thyroxine-binding globulin promoter. Mutations were introduced into wild-type hLDLR using the Quick Change lightning kit (Agilent). Serum cholesterol levels were analyzed on an MIRA analyzer (Roche). Western blotting was done using precast mini gels (Invitrogen) and probed using a polyclonal hLDLR antibody. In vitro LDLR assay was performed by transiently transfecting human embryonic kidney (HEK293) cells and pulsing the cells the following day with BODIPY-labeled LDL (Invitrogen). Data were analyzed using 1-way ANOVA models with pair-wise group differences in mean cholesterol level assessed using Tukey post hoc tests.
Results

Amino Acid Substitutions in hLDLR Confer PCSK9 Resistance
Nine LDLR variants with potentially decreased binding to PCSK9 (N295D, D299N, H306G, V307D, N309A, D310N, L311T, L318D, and L318H; Table 1 ) were initially screened in HEK293 cells using an in vitro assay for uptake of fluorescent boron-dipyrromethene labeled-LDL (BODIPY-LDL) in the presence or in the absence of hPCSK9. A list of the amino acid substitutions and their role in reducing LDLR-PCSK9 interaction is presented in Table 2 . We performed the studies in HEK293 cells that have low levels of endogenous expression of hLDLR and hPCSK9. As a source of exogenous hPCSK9, cells were cotransfected with a plasmid expressing hPCSK9 along with the hLDLR constructs. Mock-transfected cells expressed low levels of LDLR based on immunoblotting, which failed to detect LDLR protein (data not shown); moreover, mock-transfected cells failed to demonstrate uptake of BODIPY-LDL ( Figure 1A) . In contrast, transient transfection of wild-type hLDLR into HEK293 cells led to the internalization of BODIPY-LDL in 30% of cells, which was reduced to 18% when cotransfected with hPCSK9 ( Figure 1A ). Among the mutant constructs coexpressed with hPCSK9, only the D299N and L311T amino acid substitutions failed to afford any protection to PCSK9mediated degradation in that BODIPY-LDL uptake was reduced to a similar extent as wild-type LDLR. All other amino acid substitutions afforded varying degrees of protection from PCSK9 although some constructs were less efficient in BODIPY-LDL uptake in the absence of PCSK9 when compared with wild-type hLDLR. As an example, although the L318D and L318H substitutions were both resistant to hPCSK9 degradation, only L318D showed normal BODIPY-LDL uptake in the absence of PCSK9 ( Figure 1B ). In contrast, the L318H substitution led to reduced receptor activity and BODIPY-LDL uptake was lower when compared with wild-type hLDLR in the absence of hPCSK9 (30% versus 6%; hLDLR versus hLDLR-L318H). Next, we evaluated all constructs in vivo using a humanized mouse model of hoFH phenotype (lacking LDLR and APOBEC-1 by virtue of germ-line interruption). Systemic administration of 3×10 10 GC of AAV8 expressing wild-type human LDLR led to a decline in serum non-high-density lipoprotein (HDL) cholesterol by day 30 to 16% of baseline levels ( Figure 1C ). Mice administered with the novel AAV8.hLDLR variants also demonstrated reductions in non-HDL levels that varied from 10% to 20% of baseline. Interestingly, variants that did not perform well in the in vitro assay were still efficient when administered in vivo (eg, D295D). However, on the basis of in vitro and in vivo studies, we decided to investigate only the L318D variant further.
Overexpression of hPCSK9 in Mice Downregulates AAV-Expressed hLDLR
Evaluating the activity of wild-type and L318D forms of hLD-LR in mice was complicated because of potential diminished interactions between the exogenous hLDLR protein and the endogenous mouse PCSK9 protein. We used our partially humanized mouse model of hoFH and overexpressed hPCSK9 [after intravenous injection of an AAV9 vector expressing hPCSK9 via the liver-specific promoter thyroxine binding globulin [AAV9.hPCSK9]). Expression of AAV9.hPCSK9 vector was first evaluated in C57BL/6 mice, which received increasing doses of hPCSK9 (Online Figure I) . At high-dose In silico analysis was used to determine human LDLR amino acid substitutions likely to interfere with PCSK9 binding. The amino acid substitutions and the LDLR-PCSK9 interaction that is expected to be affected are presented. LDLR indicates low-density lipoprotein receptor; and PCSK9, proprotein convertase subtilisin/kexin type 9. vector (ie, 5×10 10 GC) serum non-HDL cholesterol increased ≈2.5-fold (P=0.0015), indicating some level of interaction between hPCSK9 and mLDLR.
Before evaluating the effects of hPCSK9 on transgenederived hLDLR, the hoFH DKO mice were injected with AAV8.hLDLR alone. In these animals, baseline non-HDL levels on a chow diet were 417±23 mg/dL, which decreased by day 7 after the administration of 5×10 10 GC of AAV8. hLDLR. Non-HDL levels were stabilized and were only 37±7 mg/dL by day 30, which was 9% of baseline levels (P=0.037; Figure 2A ). Next, we evaluated the performance of this vector in DKO mice expressing hPCSK9 by coadministering (intravenous) an equal dose (5×10 10 GC) of AAV9. hPCSK9 along with AAV8.hLDLR. After the vector administration, serum levels of hPCSK9 rose steadily and reached peak levels (7500±1496 ng/mL) by day 30. Concomitantly, non-HDL levels in mice cotransduced with hPCSK9 were significantly higher (P=0.0008) when compared with animals that only received hLDLR (Figure 2A ). AAV8.hLD-LR reduced non-HDL 10-fold in the absence of hPCSK9; however, this reduction was only 2.5-fold in the presence of hPCSK9. Immunoblotting of total liver lysates confirmed that cotransduction with PCSK9 resulted in reduced hLDLR protein in the liver ( Figure 2B and 2C), whereas levels of hLDLR messenger RNA remained unchanged between the experimental groups (data not shown). These findings are consistent with the reported mode of action of PCSK9 to bind and sequester LDLR in an intracellular compartment that increases receptor degradation. 19 No reduction in hLD-LR expression was observed in animals cotransduced with an AAV9 vector expressing an irrelevant transgene (Online Figure II ).
THE LDLR-L318D Amino Acid Substitution Confers Resistance to Human PCSK9-Mediated Degradation
We used a similar strategy to evaluate the activity of hLDLR-L318D in DKO mice overexpressing hPCSK9 and compared the results to mice transduced with wildtype hLDLR. As expected, transduction with hLDLR resulted in a dramatic lowering of serum cholesterol by day 30 (10% of baseline) whereas cotransduction with hPCSK9 resulted in reduced hLDLR activity with non-HDL cholesterol levels only 23% of baseline (P<0.0001; Figure 3A ). In contrast, the L318D substitution apparently prevented receptor degradation in that differences in non-HDL levels between animals that received hLD-LR-L318D or hLDLR-L318D along with hPCSK9 was not statistically significant (10% versus 14%; P=0.1337). Immunoblotting of livers collected at the end of the study (day 30) revealed that hLDLR protein levels were significantly decreased in animals that received wild-type hLDLR along with hPCSK9 when compared with those that received hLDLR alone ( Figure 3B ). However, liver levels of hLDLR-L318D were unaffected by coexpression with hPCSK9 and were comparable with those observed with wild-type hLDLR in the absence of hPCSK9 ( Figure 3B ). To confirm that the observed differences did not arise from changes in mRNA expression, we analyzed hLDLR transcripts in livers using a quantitative polymerase chain reaction assay. These studies indicated only a modest decrease in wild-type hLDLR-treated mice that were substantially less than the decrease in hLDLR protein ( Figure 3B ; Online Figure III ).
hLDLR-K809R\C818A Escapes hIDOL Regulation
LDLR expression is also subject to regulation by IDOL, an E3 ubiquitin ligase transcriptionally upregulated by liver X Figure 2 . In vivo overexpression of human proprotein convertase subtilisin/kexin type 9 (hPCSK9) leads to an increase in serum cholesterol in animals dosed with wildtype human low-density lipoprotein receptor (hLDLR). Double knockout mice (n=4 per group) were administered intravenously with a dose of 5×10 10 GC of AAV8.hLDLR or AAV8.hLDLR along with 5×10 10 GC of AAV9.hPCSK9 vector. Serum from animals before and 30 days after vector administration was analyzed for total serum cholesterol and high-density lipoprotein (HDL) cholesterol. Non-HDL cholesterol levels were determined by subtracting the HDL component from total cholesterol. A, Percentage change in day 30 non-HDL serum cholesterol relative to baseline levels in animals that received hLDLR with or without hPCSK9. B, Immunoblot of hLDLR expression in mice treated with hLDLR or hLDLR with hPCSK9. Total liver lysates from 2 representative animals per group were electrophoresed on a 4% to 12% gradient SDS gel and probed with a polyclonal anti-hLDLR goat polyclonal antibody. Mouse tubulin expression was used as a loading control. receptors after an increase in intracellular concentrations of oxysterols. Activated IDOL interacts with the cytoplasmic tail region of LDLR leading to receptor degradation. 20 Amino acid residues, lysine (K809) and cysteine (C818), in the cytoplasmic tail region of hLDLR, have previously been demonstrated to be important for regulation by IDOL. 16 On the basis of these findings, we constructed an AAV8 vector expressing hLDLR containing the K809R and C818A amino acid substitutions (AAV8.hLDLR-K808R\C818A). This construct was first evaluated in HEK293 cells in the presence or absence of hIDOL; as a source of human IDOL, we cotransfected plasmids expressing hIDOL along with hLDLR. As expected, transfection of wild-type hLDLR resulted in LDL uptake in 28% of cells; however, cotransfection of hIDOL along with hLDLR dramatically reduced LDL-positive cells to only 2% ( Figure 4A ). The K808R\ C818A amino acid substitutions did not affect receptor activity, and the LDLR-K809R\C818A construct was as efficient as wild-type hLDLR in internalizing LDL, in the absence of IDOL (LDLR versus LDLR-K809R\C818A, 28% versus 22%). However, differences between the 2 constructs did appear when cotransfected with hIDOL. The hLDLR-K809R\C818A construct was more resistant to the effects of hIDOL resulting in ≈14% of cells taking up fluorescent LDL as opposed to 2% with wild-type LDLR. Immunoblotting of whole-cell lysates further confirmed that the observed differences in LDL uptake correlated with reduced levels of hLDLR protein, and not hLDLR-K809R\ C818A, in the presence of hIDOL ( Figure 4A ; Online Figure IV ).
Next, we evaluated the activity of the hLDLR-K809R\ C818A construct in DKO mice overexpressing human IDOL. Similar to our strategy with the PCSK9 studies, we created a phenotype of mice overexpressing human IDOL in liver by administering an AAV9 vector expressing human IDOL under control of a liver-specific promoter. In pilot studies, we assessed the efficacy of human IDOL in regulating endogenous LDLR expression in mice by administering (intravenous) 5×10 10 GC of AAV9.hIDOL to FH mice heterozygous for LDLR expression (heterozygous FH). This strain of mice (human ApoB100 transgenic mice) is deficient in APOBEC-1, heterozygous for mouse LDLR +/− and transgenic for human ApoB100, which leads to higher serum cholesterol. After the administration of AAV9.hIDOL, non-HDL levels increased by day 7 and reached stable levels by day 30 (P<0.0001; Figure 4B ). These results confirmed that AAV expressed hIDOL was active in mouse livers and can cause the loss of endogenous mLDLR. Next, we investigated the effect of hIDOL overexpression on vector encoded hLDLR in DKO mice. In pilot studies, we noted that only low-dose hLDLR vector administrations were significantly affected by human IDOL. At higher doses, vector expressed LDLR was able to overcome IDOL inhibition (Online Figure V) . Hence, we coadministered mice with 3×10 9 GC of AAV8.hLDLR and 5×10 10 GC of AAV9.hIDOL. At this low dose, hLDLR and hLDLR-K809\C818A vectors were functionally similar (P=0.9) and induced a modest reduction (20% of baseline) in serum cholesterol in the absence of hIDOL ( Figure 4C ). However, coadministration of hIDOL ablated wild-type hLDLR activity, and no correction was seen in non-HDL cholesterol levels, which remained at pretreatment baseline levels (P=0.0248; Figure 4C ). In contrast, non-HDL cholesterol levels in mice that received hLDLR-K809R\C818A in the presence or in the absence of hIDOL were similar (P>0.05), demonstrating the in vivo resistance of the modified constructs to hIDOL ( Figure 4C ).
hLDLR-L318D\K809R\C818A Avoids Regulation by Both PCSK9 and IDOL
The L318D, K809R, and C818A amino acid substitutions were cloned into a single vector to create a construct that would be resistant to regulation by both pathways (Online Figure VI) . We then administered the vector to DKO mice at a low dose (3×10 9 GC), when evaluating the IDOL escape mutations, or at a high dose (5×10 10 GC), when evaluating the PCSK9 escape mutation. When administered at a low dose, hLDLR-L318D\K809R\C818A was comparable with wild-type hLDLR (P>0.05) in that only a modest decrease in serum cholesterol was realized after either vector administration ( Figure 5A ). However, when administered in the presence of hIDOL, only the mutant vector showed any resistance to hIDOL in that serum cholesterol levels remained significantly lower than that seen in wildtype hLDLR plus hIDOL (P=0.0002). Immunoblotting of liver samples confirmed that the mutant vector was more resistant to hIDOL-mediated degradation ( Figure 5A ). In the parallel study, where we administered vectors at a higher dose along with hPCSK9, the variant protein performed significantly better in reducing serum cholesterol than the Figure 5 . The AAV8.hLDLR-L318D\K809R\C818A variant encoding 3 amino acid substitutions escapes both proprotein convertase subtilisin/kexin type 9 (PCSK9) and inducible degrader of LDLR (IDOL)-mediated regulation. A, Double knockout mice (n=4 per group) were intravenously administered with 3×10 9 GC of human low-density lipoprotein receptor (hLDLR) or hLDLR-L318D\K809R\ C818A. Additional groups of mice also received a simultaneous administration of AAV9.hIDOL. Total serum cholesterol levels were evaluated before and 30 days after vector administration. Percentage decrease in non-high-density lipoprotein (HDL) cholesterol relative to baseline. Total liver lysates from 2 representative animals per group was electrophoresed on a SDS-PAGE gel and probed using an anti-hLDLR antibody along with tubulin as a loading control. B, Coadministration of AAV8.hLDLR (5×10 10 GC) or hLDLR-L318D\K809R\ C818A along with AAV9.hPCSK9 (5×10 10 GC). Percentage decrease in day 30 non-HDL cholesterol relative to baseline is shown along with an immunoblot of hLDLR expression in livers. ***P<0.001. control wild-type LDLR in mice overexpressing hPCSK9 (P=0.0007; Figure 5B ). Immunoblot analysis of livers demonstrated a nearly complete absence of wild-type hLDLR in the presence of hPCSK9; in contrast, the mutant vector was protected and less degraded by hPCSK9.
Discussion
The attractiveness of AAV gene therapy is based on the premise of life-long correction of a metabolic disorder after the single administration of a vector encoding the correct protein. 21 Although the new AAV vectors are much more efficient than the original AAV serotype 2-based vectors, the efficiency of transduction remains an important issue. This has led to a strategy to express proteins with increasing activity over the normal wild-type protein. For instance, the lipoprotein lipase gain-of-function naturally occurring mutation (S447X) has been demonstrated to prevent degradation by post-translational mechanisms; 22 a finding that has resulted in the development of the first licensed AAV gene therapy product carrying this gain-of-function mutation for lipoprotein lipase deficiency. 23 A similar approach has been pursued in gene therapy of hemophilia B using gene encoding hyperactive factor IX variant, which is in phase I studies. 24 With these cases as precedent, we undertook studies to develop variants of hLDLR that are resistant to endogenous degradation pathways as a way to improve vector potency. AAV hepatic LDLR expression is the subject to multiple pathways of regulation; of these, regulation by PCSK9 has emerged as the leading candidate for the development of second-generation lipid-lowering drugs, and several clinical studies are underway to augment LDLR expression by interfering with PCSK9-mediated degradation of the receptor. 14 More recently, a second form of post-transcriptional regulation of LDLR expression, based on the degradation of the receptor by the ubiquitin-proteasome pathway, has emerged as an additional target to increase receptor expression. 25 Such strategies to increase LDLR expression were also bolstered by reports that subjects with naturally occurring loss-offunction mutations in PCSK9 and IDOL have lower LDL-C levels but have no disease associated with these mutation 13, 17 ; therefore, avoiding LDLR degradation by these regulatory pathways should be considered to be safe and potentially helpful in improving gene therapy for hoFH.
In our previous studies, we noted that systemic administration of 5×10 12 GC/kg of AAV8.LDLR led to a dosedependent stable correction of serum cholesterol levels in humanized FH mice. 26 In the present study, we investigated the potential of novel hLDLR variants to avoid degradation by PCSK9 and IDOL as a means to increase vector efficacy. Moreover, it is possible that pathways responsible for downregulating LDLRs may be more active in FH subjects. For instance, patients with homozygous FH and heterozygous FH have higher levels of PCSK9 when compared with normal subjects. 18 It is unclear why FH subjects have increased expression of PCSK9. Although statins are known to increase PCSK9 expression, FH subjects had increased levels of PCSK9 even in the absence of statin therapy. It is possible that the increase could result from an inability to remove PCSK9 from circulation via binding to the missing LDLR.
The available crystal structure of LDLR-EGF-A domain with hPCSK9 allowed us to identify amino acid substitutions that abrogated the interaction. 27 Among these, the L318D modification conferred protection from PCSK9 both in vitro and in vivo. Although several constructs did escape PCSK9 regulation in our in vitro studies and were functional in our in vivo screening, we focused only on the L318D amino acid substitution because it had also been previously described by Zhang et al, 28 to reduce PCSK9 binding to LDLR. However, it is possible that other constructs may be more effective in avoiding degradation and could be considered in secondgeneration products. In our study, L318D conferred protection after hepatic expression in mice overexpressing PCSK9 and led to a significant decrease in serum cholesterol, whereas wild-type LDLR was less efficient and more readily degraded by PCSK9. This establishes proof-of-concept that a PCSK9resistant LDLR cDNA may be a more effective transgene for gene therapy for homozygous FH.
The K809R and C818A amino acid substitutions in hLDLR have been previously reported to prevent in vitro IDOL-mediated degradation of hLDLR. An interesting finding was the increase in serum cholesterol after the overexpression of human IDOL in LDLR +/− mice and suggests that hIDOL has some activity against mouse LDLR in terms of the endogenous ubiquitin-proteasome pathway. In our study, the K809R/C818A hLDLR double mutant conferred protection after hepatic expression in mice expressing hIDOL and led to a significant decrease in serum cholesterol, whereas wild-type LDLR was less efficient and more readily degraded by IDOL. Our studies thus establish that amino acid modifications in LDLR can also overcome in vivo IDOL-mediated suppression. Escape from IDOL-mediated degradation was not complete and may indicate the involvement of other LDLR residues with IDOL. For instance, amino acids 816, 817, and 821 to 823 have all been reported to be involved in the interaction with IDOL, and substitution of these residues leads to decreased LDLR degradation by IDOL. 29 Incorporating these additional amino acid substitutions may lower IDOL degradation of LDLR; however, multiple amino acid substitutions can efface transgene expression if the modified transgenes are sufficiently different to trigger an adaptive immune response. Moreover, we noted that overexpression of LDLR can overcome some of the negative regulatory effects of IDOL. However, AAV8.LDLR expression is expected to vary significantly in subjects and the incorporation of IDOL escape mutations may be more relevant in those subjects who receive lower doses of vector or have lower levels of LDLR expression.
Factors that lead to LDLR degradation are expected to be higher in subjects lacking endogenous receptor expression because of lack of a substrate to remove the inhibitors. This could argue for the consideration of these gain-of-function transgene variants to reduce clearance by these pathways. A potential caveat with this approach is the development of an adaptive immune response to the transgenes encompassing the mutated amino acids. However, systemically administered AAV vectors have demonstrated to be safe and rarely induce an adaptive immune response to the transgenes 30 ; moreover, even when present, activated T cells are known to ignore AAV8 transduced hepatocytes. 31 In support of these findings, administration of the hyperactive factor IX variant FIX-R338L to hemophilia B dogs did not elicit a T-cell response to the transgene. 24 However, adaptive immunity accompanied by strong inflammatory signals is known to eliminate AAV transduced cells, 32 suggesting that CTL responses to the new variants in the presence of inflammation need to be investigated in detail. In conclusion, we demonstrate here the usefulness of LDLR variants in overcoming negative cellular regulatory pathways, known to exist in FH subjects. The findings presented here demonstrate for the first time the successful use of an AAV encoded gain-of-function transgene in reducing cholesterol in partially humanized mouse models and could be considered in the development of more effective gene therapy products for hoFH.
